The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

The money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...